Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes

Annals of Hematology

Volumn 87, Issue 9, 2008, Pages 691-699

  Germing, Ulrich ^a   Aul, Carlo ^b   Niemeyer, Charlotte M ^c   Haas, Rainer ^a   Bennett, John M ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Classification; FAB; Myelodysplastic syndromes; WHO

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL; BLOOD TRANSFUSION; CANCER RISK; CELL COUNT; CELL LINE; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DOWN SYNDROME; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; WORLD HEALTH ORGANIZATION;

ADULT; CHILD; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 48649093537     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0499-3     Document Type: Review

References (55)

1. Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
2. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52-59
3. Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R, Gattermann N (2004) No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 89:905-910
4. Ma X, Does M, Raza A, Mayne ST (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109(8):1536-1542
5. Kündgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U (2006) Myelodysplastic syndromes under the age of 50 years. J Clin Oncol 24(34):5358-5365
6. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Tomonaga M (2005) Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 106(8):2633-2640
7. Kuendgen A, Matsuda A, Germing U (2007) Differences in epidemiology of MDS between western and eastern countries: Ethnic differences or environmental influence? Leuk Res 31(1):103-104
8. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, Head DR (2003) A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17(2):277-282
9. Stary J, Baumann I, Creutzig U et al (2008) Getting the numbers straight in pediatric MDS: Distribution of subtypes after exclusion of down syndrome. Pediatr Blood Cancer 50:435-436
10. Gattermann N, Aul C, Schneider W (1990) Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 74:45-52
11. Garand R, Gardais J, Bizet M et al (1992) Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res 16:463-468
12. Germing U, Gattermann N, Aivado M et al (2000) Two types of acquired idiopathic sideroblastic anaemia (AISA): A time-tested distinction. Br J Haematol 108:724-728
13. Rosati S, Mick R, Xu F et al (1996) Refractory cytopenia with multilineage dysplasia: Further characterization of an 'unclassifiable'myelodysplastic syndrome. Leukemia 10:20-26
14. Balduini CL, Guarnone R, Pecci A et al (1998) Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes. Leukemia 12:1655-1656
15. Matsuda A, Jinnai I, Yagasaki F et al (1998) Refractory anemia with severe dysplasia: Clinical significance of morphological features in refractory anemia. Leukemia 12:482-485
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C, Cox C (1994) The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87(4):746-754
17. Germing U, Gattermann N, Minning H et al (1998) Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 22:871-878
18. Neuwirtova R, Mocikova K, Musilova J et al (1996) Mixed myelodysplastic and myeloproliferative syndromes. Leuk Res 20:717-726
19. Sanz GF, Sanz MA, Vallespí T, Cañizo MC, Torrabadella M, García S, Irriguible D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74(1):395-408
20. Strupp C, Gattermann N, Giagounidis A et al (2003) Refractory anemia with excess of blasts in transformation: Analysis of reclassification according to the WHO proposals. Leuk Res 27:397-404
21. Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds) (2001) WHO classification of tumours: Tumours of haematoloietic and lymphoid tissues. IARC, Lyon
22. Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131-133
23. Germing U, Gattermann N, Strupp C et al (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983-992
24. Lorand-Metze I, Pinheiro MP, Ribeiro E et al (2004) Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 28:587-594
25. Lee JH, Lee JH, Shin YR et al (2003) Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 17:305-313
26. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23(30):7594-7603
27. Breccia M, Carmosino I, Biondo F, Mancini M, Russo E, Latagliata R, Alimena G (2006) Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes. Leuk Res 30(2):178-182
28. Nosslinger T, Reisner R, Koller E et al (2001) Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98:2935-2941
29. Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91(12):1596-1604
30. Rong A, Gattermann N, Germing U, Aul C, Aivado M (2000) RAS Mutations are rare in acquired idiopathic sideroblastic anemia (AISA) and apparently absent in pure sideroblastic anemia (PSA). Onkologie 23(Suppl 7):A181
31. Howe RB, Porwit-MacDonald A, Wanat R et al (2004) The WHO classification of MDS does make a difference. Blood 103:3265-3270
32. Cermák J, Belicková M, Krejcová H, Michalová K, Zilovcová S, Zemanová Z, Brezinová J, Sieglová Z (2005) The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. Leuk Res 29(4):371-379
33. Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A, Strupp C, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Gattermann N, Aul C, Tomonaga M (2007) Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia 21(4):678-686 (Apr)
34. Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N, Bennett JM (2007) Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 92(7):974-977
35. Schmitt-Graeff A, Thiele J, Zuk I et al (2002) Essential thrombocythemia with ringed sideroblasts: A heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 87:392-399
36. Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A, Reinecke P, Germing U, Skoda RC (2008) JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 93(1):34-40
37. Zipperer E, Wulfert M, Germing U, Haas R, Gattermann N (2007) MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 × 10(9)/l. Ann Hematol 87:413-415
38. Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F, Criel A, Selleslag D (2007) High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 109(3):1334-1335
39. Tuzuner N, Cox C, Rowe JM et al (1995) Hypocellular myelodysplastic syndromes (MDS): New proposals. Br J Haematol 91:612-617
40. Marisavljevic D, Rolovic Z, Cemerikic V, Boskovic D, Colovic M (2004) Myelofibrosis in primary myelodysplastic syndromes: Clinical and biological significance. Med Oncol 21(4):325-331
41. Büsche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Göhring G, Schlegelberger B, Bock O, Georgii A, Kreipe H (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313-322
42. Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A, Aul C, Haas R, Germing U (2008) Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res 32(1):33-37
43. Giagounidis AA, Germing U, Haase S et al (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113-199
44. Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR, StarýJ, Schmitt-Graeff A, Fischer A, Harbott J, Chessells JM, Hann I, Fenu S, Cantú Rajnoldi A, Kerndrup G, van Wering E, Rogge T, Nöllke P, Niemeyer CM (2003) Refractory anemia in childhood: A retrospective analysis of 67 cases with particular reference to monosomy 7. Blood 102:1997-2003
45. Hasle H, Baumann I, Bergstrasser E, Fenu S, Fischer A, Kardos G, Kerndrup G, Locatelli F, Rogge T, Schultz KR, Stary J, Trebo M, van den Heuvel-Eibrink MM, Harbott J, Nollke P Niemeyer CM (2004) The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 18:2008-2014
46. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59(3):425-433
47. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7(9):1315-1323
48. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett JM (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088
49. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Mueller T, Haas R, Gattermann N, Aul C (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19(12):2223-2231
50. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110(13):4385-4395, Dec 15
51. van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ (2008) Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 111(3):1067-1077
52. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter B, Sperr WR, Stauder R, Wells DA (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31(6):727-736
53. Malcovati L, Germing U, Kuendgen A, DellaPorta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510
54. Pelz D, Nachtkamp K, Kündgen A, Strupp C, Haas R, Germing U (2007) Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS). Leuk Res Suppl 1 Abstract
55. Della Porta MG, Malcovati L, Travaglino E, Pascutto C, Maffioli M, Invernizzi R, Cazzola M (2007) A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. Blood 110:ABstr. 2453